BRIM Biotechnology | Team

Team

BRIM Biotechnology brings together experts across science, engineering, and technology disciplines to deliver a more efficient, less costly, drug development process. Our talented team has forged decades worth of strong global connections and experience. We operate based on a virtual biotechnology model, integrating our expert R&D operation team in Taiwan with our skilled overseas scientific team. We have years of experience working in technological and pharmaceutical development, regulatory affairs, and marketing and IP, with expertise across the field of innovative drug development, including pre-clinical toxicology, clinical pharmacology and management. We harness the power of our team’s expertise in translational science to deliver a difference for patients.

BRIM
Flower
Translational Science Expertise
Pre-clinical & Toxicology
Dr. Frank Lee
Dr. Frank Lee
Chief Strategy Officer & BRIM Cayman Chairman
Dr. Frank Lee
Dr. Frank Lee
Chief Strategy Officer & BRIM Cayman Chairman
Dr. Carl Alden
Dr. Carl Alden
Senior Fellow
Dr. Carl Alden
Dr. Carl Alden
Senior Fellow
Previously Vice President at Millennium
Held various roles at Searle, Monsanto, Pharmacia & P&G
Served as Editor of Veterinary Pathology and Toxicology Pathology and President at Society of Toxicology Pathologist
Clinical Pharmacology & Clinical Management
Dr. Haishan Jang
Dr. Haishan Jang
Chairwoman & Chief Executive Officer
Dr. Haishan Jang
Dr. Haishan Jang
Chairwoman & Chief Executive Officer
Dr. Conrad Tou
Dr. Conrad Tou
Senior Fellow
Dr. Conrad Tou
Dr. Conrad Tou
Senior Fellow
30+ years of experience in biotech and large pharmaormer director at Hollis-Eden pharma
Held several positions at Sanofi-Winthrop and AstraZeneca, with expertise in statistics and data management
CMC & Pharmaceutical Development
Dr. Wayne Liaw
Dr. Wayne Liaw
Senior Fellow
Dr. Wayne Liaw
Dr. Wayne Liaw
Senior Fellow
Previously held Senior Director positions at Otonomy and Optimer
Former director at Hollis-Eden pharma
Regulation
Su Lin
Su Lin
VP of Operation
Su Lin
Su Lin
VP of Operation
Marketing and IP
Dr. Chyau Liang
Dr. Chyau Liang
Senior Fellow
Dr. Chyau Liang
Dr. Chyau Liang
Senior Fellow
Previously Partner at Osha Liang LLP
Former Professor at the University of Texas-Houston School of Medicine
SABs & KOLs
Dr. Pan-Chyr Yang
Dr. Pan-Chyr Yang
Scientific Board Member
Dr. Pan-Chyr Yang
Dr. Pan-Chyr Yang
Scientific Board Member
Academician at Academia Sinica and Professor at National Taiwan University
Previously President of National Taiwan University
Editor-in-Chief of MicroRNA and Lung Cancer: Targets and Therapy
Dr. Robert Ruffolo
Dr. Robert Ruffolo
Scientific Board Member
Dr. Robert Ruffolo
Dr. Robert Ruffolo
Scientific Board Member
Previously President of R&D and Corporate Senior Vice President of Wyeth Pharmaceuticals
Senior Vice President and Director of Research at SmithKline Beecham Pharmaceuticals
Chairman of the Cardiovascular Research Committee at Eli Lilly & Company
Dr. Wen Chyi Shyu
Dr. Wen Chyi Shyu
Scientific Board Member
Dr. Wen Chyi Shyu
Dr. Wen Chyi Shyu
Scientific Board Member
Vice President of Global Drug Metabolism and Pharmacokinetics at Takeda
30+ years of experience in drug metabolism and pharmacokinetics
Dr. Eliot Lazar
Dr. Eliot Lazar
Scientific Board Member
Dr. Eliot Lazar
Dr. Eliot Lazar
Scientific Board Member
CEO at elCON Medical Consulting
Previously held Assistant Professor positions at the State University of NY and the University of Rochester

Leadership

Haishan

Dr. Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J). She was Senior Director of Biologics Clinical Pharmacology at Centocor.

Frank

Dr. Lee received his Ph.D in Medical Chemistry from UC San Francisco. He was formerly the VP of DMPK at Millennium Pharmaceuticals (Takeda). He has over 40 years of R/D experience in global pharmaceutical companies, with expertise in DMPK, PK/PD, drug candidate selection and FIH strategy. He participated in the development of 15 U.S. FDA approved new drugs.

Erin

VP Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University. She has more than 15 years of experience in new drug development and project management. She has worked at TTY Biopharm and Taiwan Liposome Company. VP Chang has participated in the discovery and clinical development of biologics, peptide,  and special dosage new drugs.

Su Lin

VP Lin has her Masters of Science in Hospital pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years of experience in the pharmaceutical industry, specifically in regulatory affairs and labeling. She has worked in global pharmas such as  Regeneron Pharmaceuticals.

Maria

Dr. Chen is a cellular immunologist, specializing in the study of T cell and B cell activities. Dr. Chen received her PhD in Biochemistry at the State University of New York at Stony Brook and did post-doctoral research at UCSF and Genentech. Dr. Chen returned to Taiwan in 2015 and has devoted herself to the development of new drugs and the business development of startup companies.

Ben Wu

VP Wu graduated from National Cheng Kung University with a bachelor degree in accountancy and received his Master of Accountancy at Golden Gate University in the USA. He has worked with startups and listed companies over 20 years and established a great experience in various aspects of finance and accounting.

Senior Scientific Team

Carl Alden

Dr. Alden is a veterinarian by training with more than 40 years of pharmaceutical industry toxicology/pathology experience at companies such as Millennium, Searle, Monsanto, Pharmacia, and Procter & Gamble. He retired as the VP of Toxicology at Millennium Pharmaceuticals (Takeda).

Conrad Tou

D. Tou has over 30 years of work experience in biotech and major pharmaceutical companies, such as Sanofi-Synthelabo, Sterling-Winthrop, P&G, and AstraZeneca. He was formerly the associate director of Statistics at AstraZeneca, and has expertise in statistics and data management.

Chyau Liang

Dr. Liang has more than 30 years of experience. He is a senior partner at Osha Liang LLP, US lawyer, patent attorney, Taiwan patent attorney, and he is a former professor at the University of Texas-Houston School of Medicine. He is experienced in international patents, strategy analysis, patent application & litigation, IP management and consultant.

Wayne Liaw

Dr. Liaw has more than 30 years of experience in formulation and CMC. He has developed drug formulations in small molecule, big molecule, and peptide. He was responsible for senior management in U.S. companies such as Syntex and Optimer Biotech.